The Department of Justice reaffirmed its longstanding policy that Title III of the Americans with Disabilities Act (ADA) applies to websites, though once again, it declined to issue specific regulations on what websites need to do to comply with the law. In this POV from our user experience expert, Amy Toft, we explain the importance of accessibility, how adherence to Title III affects websites, and how making content accessible to all users affects pharma.
On October 16, 2018, the Food & Drug Administration (FDA) released a new draft guidance titled Presenting Quantitative Efficacy and Risk Information in Direct-to-Consumer Promotional Labeling and Advertisements. In this POV from Intouch’s external regulatory expert Dale Cooke, we provide an overview of the guidance and offer recommendations for ensuring consumers and healthcare professionals understand promotional communications.
In this POV from Intouch, we discuss the short- and long-term impacts of sharing drug prices with consumers and offer recommendations on how marketers of prescription products should proceed in light of these developments.